Amicus Therapeutics Launches Treatment of Fabry Disease in Spain

- January 18th, 2018

Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Spain following final pricing and reimbursement decisions. As quoted in the press release: “The commercial launch of Galafold in Spain adds to the tremendous momentum in expanding our launch … Continued

Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Spain following final pricing and reimbursement decisions.
As quoted in the press release:

“The commercial launch of Galafold in Spain adds to the tremendous momentum in expanding our launch throughout the EU, where we have now secured reimbursement in all five countries that have the largest Fabry populations within the EU,” stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc.

Click here to view the full press release.

Top 5 Biotech Stocks to Watch This Year

 
Find out how other investors are profiting from biotech

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *